Table 3. Per Protocol Rates of Completion, No. (%).
| Outcome | No./total No. (%) | |||
|---|---|---|---|---|
| Standard message | Tailored message | Control group | Total | |
| WCC scheduled within 2 wk | 59/312 (18.9) | 44/286 (15.4) | 30/315 (9.5) | 133/913 (14.6) |
| WCC completed within 8 wk | 76/312 (24.4) | 54/286 (18.9) | 40/315 (12.7) | 170/913 (18.6) |
| Receipt of COVID vaccination within 8 wka | 14/81 (17.3) | 2/74 (2.7) | 3/82 (3.7) | 19/237 (8.0) |
| Receipt of DTaP within 8 wka | 6/32 (30.0) | 6/31 (30.0) | 8/32 (40.0) | 20/95 (21.1) |
| Receipt of HPV within 8 wka | 12/47 (48.0) | 6/46 (24.0) | 7/50 (28.0) | 25/143 (17.5) |
| Receipt of MCV4 within 8 wka | 10/54 (33.3) | 11/53 (36.7) | 9/49 (30.0) | 30/156 (19.2) |
Abbreviations: HPV, human papillomavirus vaccine; MCV4, meningococcal conjugate vaccine; DTaP, diphtheria and tetanus toxoids and acellular pertussis; WCC, well child care.
a
Analysis includes all patients eligible to receive this vaccine during the 8-week study period.